Multicenter single-blind randomized clinical trial of parenteral piperacillin-sulbactam(4:1) in the treatment of acute bacterial infections

Objective To evaluate the clinical efficacy and safety of domestic injectable piperacillin - sulbactam for the treatment of acute moderate and severe bacterial infections. Methods A multicenter, single - blind, randomized clinical trial was carried. Piperacillin - sulbactam (trial) was administered intravenously at a dose of 5 g thrice daily for 5 to 10 days. And piperacillin - tazobactam (control) was administered intravenously at a dose of 4. 5 g thrice daily for 5 to 10 days. A total of 215 patients (107trial, 108 control) with respiratory or urinary tract infections were enrolled in the study Results At the end of the treatment, the cure rate and effective rate were 77. 67％ and 93. 20％ in trail; while 75. 47％ and 93. 40％ in control. The bacterial eradication rates were 95. 0％ and 97. 59％ , respectively. There was no statistical difference between the two groups (P0. 05). Adverse reactions were observed in 7.69％ and 8.33％ of patients in the two groups. Conclusion Domestic injectable piperacillin - sulbactam is effective and safe for the treatment of acute moderate and severe bacterial infections.